|
Advertisement | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Journal of Lipid Research, Vol. 50, 658-666, April 2009 Chemical synthesis, pharmacological characterization, and possible formation in unicellular fungi of 3-hydroxy-anandamide1
* Endocannabinoid Research Group, Institutes of Cybernetics Consiglio Nazionale delle Ricerche, Pozzuoli (Napoli), Italy 1 This work is dedicated to the memory of Prof. Santosh Nigam, deceased on October 2, 2007, and of Prof. Michael J. Walker, deceased on January 5, 2008. Published, JLR Papers in Press, November 17, 2008.
2 To whom correspondence should be addressed. e-mail.: vdimarzo{at}icmib.na.cnr.it
The fungal pathogen Candida albicans transforms arachidonic acid (AA) into 3-hydroxyarachidonic acid [3(R)-HETE], and we investigated if its nonpathogenic and 3(R)-HETE-producing close relative, Dipodascopsis uninucleata, could similarly transform the endocannabinoid/endovanilloid anandamide into 3-hydroxyanandamide (3-HAEA). We found that D. uninucleata converts anandamide into 3-HAEA, and we therefore developed an enantiodivergent synthesis for this compound to study its pharmacological activity. Both enantiomers of 3-HAEA were as active as anandamide at elevating intracellular Ca2+ via TRPV1 receptors overexpressed in HEK-293 cells, while a
Supplementary key words cannabinoid vanilloid TRPV1 CB1 CB2 endocannabinoid endovanilloid yeasts inflammation pain
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Advertisement | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||